Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Psoriasis: HELP
Articles by Ari Michael Goldminz
Based on 11 articles published since 2010
(Why 11 articles?)

Between 2010 and 2020, A. M. Goldminz wrote the following 11 articles about Psoriasis.
+ Citations + Abstracts
1 Review Psoriasis. 2016

Greb, Jacqueline E / Goldminz, Ari M / Elder, James T / Lebwohl, Mark G / Gladman, Dafna D / Wu, Jashin J / Mehta, Nehal N / Finlay, Andrew Y / Gottlieb, Alice B. ·Tufts University School of Medicine, Boston, Massachusetts, USA. · Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, USA. · Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA. · Ann Arbor Veterans Affairs Hospital, Ann Arbor, Michigan, USA. · Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. · University of Toronto, Toronto, Ontario, Canada. · Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada. · Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, USA. · National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. · Department of Dermatology and Wound Healing, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK. · Department of Dermatology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, New York 10595, USA. ·Nat Rev Dis Primers · Pubmed #27883001.

ABSTRACT: Psoriasis is a chronic, immune-mediated disorder with cutaneous and systemic manifestations and substantial negative effects on patient quality of life. Psoriasis has a strong, albeit polygenic, genetic basis. Whereas approximately half of the accountable genetic effect of psoriasis maps to the major histocompatibility complex, >70 other loci have been identified, many of which implicate nuclear factor-κB, interferon signalling and the IL-23-IL-23 receptor axis. Psoriasis pathophysiology is characterized by abnormal keratinocyte proliferation and immune cell infiltration in the dermis and epidermis involving the innate and adaptive immune systems, with important roles for dendritic cells and T cells, among other cells. Frequent comorbidities are rheumatological and cardiovascular in nature, in particular, psoriatic arthritis. Current treatments for psoriasis include topical agents, photo-based therapies, traditional systemic drugs and biologic agents. Treatments can be used in combination or as monotherapy. Biologic therapies that target specific disease mediators have become a mainstay in the treatment of moderate-to-severe disease, whereas advances in the treatment of mild-to-moderate disease have been limited.

2 Review Psoriasis Trends and Practice Gaps. 2016

Gottlieb, Alice B / Greb, Jacqueline E / Goldminz, Ari M. ·Department of Dermatology, Tufts Medical Center, 800 Washington Street, Box 114, Boston, MA 02111, USA. Electronic address: Agottlieb@tuftsmedicalcenter.org. · Department of Dermatology, Tufts Medical Center, 800 Washington Street, Box 114, Boston, MA 02111, USA. ·Dermatol Clin · Pubmed #27363878.

ABSTRACT: The present article addresses several high-impact practice gaps affecting psoriatic patients, current practices, the barriers that prevent the delivery of optimal care, and recommendations to improve patient outcomes. Discussions of treatment, cardiovascular risk factor screening, psoriatic arthritis screening, and biologics are included. Finally, an overview of current resident exposure to psoriatic care and recommendations for improvements in resident education are made.

3 Review NF-κB: an essential transcription factor in psoriasis. 2013

Goldminz, A M / Au, S C / Kim, N / Gottlieb, A B / Lizzul, P F. ·Department of Dermatology, Tufts Medical Center, Boston, MA 02111, USA. ari.goldminz@gmail.com ·J Dermatol Sci · Pubmed #23219896.

ABSTRACT: Nuclear factor kappa B (NF-κB) is a protein transcription factor that orchestrates inflammation and other complex biological processes. It is a key regulatory element in a variety of immune and inflammatory pathways, in cellular proliferation and differentiation and in apoptosis. Therefore NF-κB is a crucial mediator involved in the pathogenesis of psoriasis. Psoriasis, an inflammatory dermatosis, is marked by elevated levels of active, phosphorylated NF-κB. Genomic studies have also linked psoriasis with mediators in the NF-κB pathway. NF-κB has been hypothesized to connect the altered keratinocyte and immune cell behavior that characterizes the psoriatic milieu. Several anti-psoriatic therapies, including tumor necrosis factor-α blockers and glucocorticoids, reduce active NF-κB levels and related down-stream elements, and other biologics currently in development, including interleukin-17 blockers, may also target this pathway. Compounds that specifically target NF-κB signaling may be developed as novel therapeutics for chronic inflammatory disorders including psoriasis. However, chronic NF-κB inhibition could also result in immunodeficiencies. Therefore, a delicate balance must be found that maximizes therapeutic potential while limiting harmful effects, and may be achieved through several possible approaches, including localized therapy, selective inhibition of NF-κB signaling in pathologic cells, incomplete pathway inhibition or short treatment durations.

4 Review Ustekinumab for psoriasis and psoriatic arthritis. 2012

Goldminz, Ari Michael / Gottlieb, Alice Bendix. ·Department of Dermatology, Tufts Medical Center, Boston, Massachusetts 02111, USA. agottlieb@tuftsmedicalcenter.org ·J Rheumatol Suppl · Pubmed #22751602.

ABSTRACT: Ustekinumab, which is approved for the treatment of moderate to severe psoriasis, has been shown in phase II clinical trials to be efficacious in controlling the signs and symptoms of psoriatic arthritis. Ustekinumab appears to be well tolerated, but its longterm safety profile is not yet known.

5 Article Insights on methotrexate in psoriatic disease. 2016

Greb, Jacqueline E / Goldminz, Ari M / Gottlieb, Alice B. ·Department of Dermatology, Tufts Medical Center, 800 Washington Street, Box 114, Boston, Massachusetts, 02111, USA; Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts, 02111, USA. Electronic address: jegreb@gmail.com. · Department of Dermatology, Tufts Medical Center, 800 Washington Street, Box 114, Boston, Massachusetts, 02111, USA; Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts, 02111, USA. Electronic address: ari.goldminz@gmail.com. · Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts, 02111, USA. Electronic address: alice.gottlieb@gmail.com. ·Clin Immunol · Pubmed #27455859.

ABSTRACT: The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.

6 Article Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis. 2016

Rothstein, Brooke E / McQuade, Brianna / Greb, Jacqueline E / Goldminz, Ari M / Gottlieb, Alice B. · ·J Drugs Dermatol · Pubmed #27168275.

ABSTRACT: We report a 67-year-old Caucasian man with a long-term history of recalcitrant plaque psoriasis and psoriatic arthritis who was initiated on a treatment regimen of apremilast and secukinumab after failing multiple topical, photo, and systemic therapies. This combination provided significant skin improvement with minimal drug side effects.

J Drugs Dermatol. 2016;15(5):648-649.

7 Article CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial. 2015

Goldminz, Ari M / Suárez-Fariñas, Mayte / Wang, Andrew C / Dumont, Nicole / Krueger, James G / Gottlieb, Alice B. ·Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. · Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York. ·JAMA Dermatol · Pubmed #25946554.

ABSTRACT: IMPORTANCE: Methotrexate is a first-line systemic agent for treating of psoriasis, although its onset of effects is slower and overall it is less effective than tumor necrosis factor blockers. OBJECTIVE: To differentiate the response of psoriatic disease to adalimumab and methotrexate sodium. DESIGN, SETTING, AND PARTICIPANTS: Single-center, randomized, assessor-blind, 2-arm clinical trial of 30 patients from the outpatient dermatology center of Tufts Medical Center, enrolled from August 18, 2009, to October 11, 2011. Patients aged 18 to 85 years with chronic plaque-type psoriasis, a minimum Physician Global Assessment score of 3 (higher scores indicate more severe disease), and a psoriatic plaque of at least 2 cm were randomized in a 1:1 fashion to receive subcutaneous adalimumab or oral methotrexate. Skin biopsy specimens obtained at baseline and weeks 1, 2, 4, and 16 were given a histologic grade by blinded assessors to evaluate treatment response. Analyses were conducted from April 16, 2013, to January 5, 2015. INTERVENTIONS: A 16-week course of subcutaneous adalimumab (40 mg every 2 weeks after a loading dose) or low-dosage oral methotrexate sodium (7.5-25 mg/wk). MAIN OUTCOMES AND MEASURES: Changes in genomic, immunohistochemical, and messenger RNA (mRNA) profiles. RESULTS: Methotrexate responders experienced significant downregulation of helper T-cell-related (T(H)1, T(H)17, and T(H)22) mRNA expression compared with methotrexate nonresponders. Comparisons among adalimumab-treated patients were limited by the number of nonresponders (n = 1). Between adalimumab and methotrexate responders, we found no significant differences in gene expression at any study point or in the expression of T-cell-related mRNA at week 16. Adalimumab responders demonstrated early downregulation of chemokine (C-C motif) ligand 20 (CCL20) mRNA (mean [SE] at week 2, -1.83 [0.52], P < .001; week 16, -3.55 [0.54], P < .001) compared with late downregulation for methotrexate responders (week 2, 0.02 [0.51], P = .96; week 16, -2.96 [0.51], P < .001). Similar differences were observed with interleukin 22 (IL22) mRNA showing early downregulation for adalimumab responders (week 2, -3.17 [1.00], P < .001; week 16, -3.58 [1.00], P < .001) compared with late downregulation for methotrexate responders (week 2, -0.44 [0.68], P = .64; week 16, -5.14 [0.68], P < .001). Analysis of variance findings for key mRNA and immunohistochemical marker expression over the study course were significant only for CCL20 (P = .03) and IL22 (P = .006) mRNA comparing adalimumab and methotrexate responders. CONCLUSIONS AND RELEVANCE: Methotrexate is an immunomodulator with effects on helper T-cell signaling in psoriasis. Similar genomic and immunohistochemical response signatures and levels of mRNA downregulation at study completion among adalimumab and methotrexate responders suggest a disease-driven instead of therapeutic-driven pathway regulation. Adalimumab and methotrexate responses are differentiated by patterns of normalization of CCL20 and IL22 mRNA expression and may explain the varied onset and degree of clinical responses by each treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00932113.

8 Article Prevalence of the metabolic syndrome in children with psoriatic disease. 2013

Goldminz, Ari M / Buzney, Catherine D / Kim, Noori / Au, Shiu-Chung / Levine, Danielle E / Wang, Andrew C / Volf, Eva M / Yaniv, Shimrat S / Kerensky, Todd A / Bhandarkar, Manasa / Dumont, Nicole M / Lizzul, Paul F / Loo, Daniel S / Kulig, John W / Brown, Mary E / Lopez-Benitez, Jorge M / Miller, Laurie C / Gottlieb, Alice B. ·Tufts University, School of Medicine, Boston, Massachusetts. ·Pediatr Dermatol · Pubmed #24016334.

ABSTRACT: Adults with psoriasis have a greater risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), but few studies have investigated the prevalence of MetS and other risk factors for CVD in children with psoriasis. In an assessor-blinded study, 20 children ages 9-17 years with a current or previously documented history of psoriasis involving 5% or more of their body surface area or psoriatic arthritis were compared with a cohort of age- and sex-matched controls with benign nevi, warts, or acne. MetS, our primary endpoint, was defined by the presence of abnormal values in at least three of the following measures: triglycerides, high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), waist circumference, and blood pressure. Secondary endpoints included high-sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C). Thirty percent (6/20) of children with psoriasis met the criteria for MetS, compared with 5% (1/20) of the control group (p < 0.05). Subjects with psoriasis had higher mean FBG (91.1 mg/dL) than the control group (82.9 mg/dL) (p = 0.01). There were no statistically significant differences in the other four components of MetS, BMI, BMI percentile, hs-CRP, TC, or LDL-C. The results of this trial demonstrate that children with psoriasis have higher rates of MetS than age- and sex-matched controls. It may therefore be important to evaluate children with psoriasis for components of MetS to prevent future CVD morbidity and mortality.

9 Article Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. 2013

Au, Shiu-Chung / Goldminz, Ari M / Kim, Noori / Dumont, Nicole / Michelon, Melissa / Volf, Eva / Hession, Meghan / Lizzul, Paul F / Andrews, Israel D / Kerensky, Todd / Wang, Andrew / Yaniv, Shimrat / Gottlieb, Alice B. ·Department of Dermatology, Tufts Medical Center, Boston, MA 02111, USA. SAu@tuftsmedicalcenter.org ·J Dermatolog Treat · Pubmed #22390688.

ABSTRACT: BACKGROUND: Palmoplantar psoriasis is a variant of psoriasis resistant to many forms of treatment. METHODS: Twenty subjects with moderate-to-severe psoriasis of the palms and soles, 50% with pustules at baseline, were treated with ustekinumab at weeks 0, 4, and 16. All subjects had previously failed topical corticosteroids. Dosing was 45 mg subcutaneously for subjects weighing <100 kg and 90 mg for subjects weighing ≥100 kg. The primary endpoint was the percent of subjects achieving clinical clearance at week 16, defined as Palm-Sole Physician's Global Assessment ≤1. The study received Tufts Medical Center IRB approval. RESULTS: After 16 weeks of treatment, 35% (7/20) of subjects achieved clinical clearance. Sixty percent (12/20) improved two or more points on the Palm-Sole Physician's Global Assessment scale. Sixty-seven percent (6/9) of those receiving the 90 mg ustekinumab dose achieved clinical clearance compared with nine percent (1/11) receiving 45 mg (p = 0.02). At 24 weeks, mean values showed 56% improvement in Dermatology Life Quality Index, and 34% improvement in pain Visual Analogue Scale score (all p < 0.05). LIMITATIONS: Assessment tools for palmoplantar psoriasis are not yet validated. Five subjects withdrew or were lost to follow-up. CONCLUSION: This study demonstrates that ustekinumab dosed at 90 mg is effective in controlling signs and symptoms of palmoplantar psoriasis.

10 Minor Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin. 2016

Goldminz, Ari M / Suárez-Fariñas, Mayte / Wang, Andrew C / Dumont, Nicole / Krueger, James G / Gottlieb, Alice B. ·Department of Dermatology, Tufts Medical Center, Boston, MA, United States, United States. Electronic address: ari.goldminz@gmail.com. · Laboratory of Investigative Dermatology, The Rockefeller University, NY, NY, United States, United States. · Department of Dermatology, Tufts Medical Center, Boston, MA, United States, United States. ·J Dermatol Sci · Pubmed #27005302.

ABSTRACT: -- No abstract --

11 Minor Association between pediatric psoriasis and the metabolic syndrome. 2012

Au, Shiu-chung / Goldminz, Ari M / Loo, Daniel S / Dumont, Nicole / Levine, Danielle / Volf, Eva / Michelon, Melissa / Wang, Andrew / Kim, Noori / Yaniv, Shimrat / Lizzul, Paul F / Kerensky, Todd / Lopez-Benitez, Jorge M / Natter, Marc / Miller, Laurie / Pelajo, Christina F / Davis, Trevor / Gottlieb, Alice B. · ·J Am Acad Dermatol · Pubmed #22583717.

ABSTRACT: -- No abstract --